S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:KRBP

Kiromic BioPharma Stock Forecast, Price & News

$8.75
+0.52 (+6.32 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.24
Now: $8.75
$8.76
50-Day Range N/A
52-Week Range
$8.01
Now: $8.75
$11.90
Volume18,259 shs
Average Volume17,562 shs
Market Capitalization$64.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare products, such as mouthwash. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRBP
CUSIPN/A
CIKN/A
Phone832-968-4888
Employees13

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$64.16 million
Next Earnings DateN/A
OptionableNot Optionable
$8.75
+0.52 (+6.32 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kiromic BioPharma (NASDAQ:KRBP) Frequently Asked Questions

What stocks does MarketBeat like better than Kiromic BioPharma?

Wall Street analysts have given Kiromic BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kiromic BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Kiromic BioPharma's key competitors?

Who are Kiromic BioPharma's key executives?

Kiromic BioPharma's management team includes the following people:
  • Dr. Maurizio Chiriva Internati Ph.D., Chairman, CEO & Pres (Age 51)
  • Mr. Tony Tontat, CFO, COO & Director (Age 54)
  • Mr. Gianluca Rotino, Chief Strategy and Innovation Officer & Director (Age 47)
  • Dr. David M. Spencer, Chief Scientific Officer (Age 58)
  • Dr. Scott Dahlbeck Pharm.D., M.D., PharmD, Chief Medical Officer (Age 58)

When did Kiromic BioPharma IPO?

(KRBP) raised $16 million in an initial public offering on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager.

What is Kiromic BioPharma's stock symbol?

Kiromic BioPharma trades on the NASDAQ under the ticker symbol "KRBP."

When did Kiromic BioPharma's quiet period expire?

Kiromic BioPharma's quiet period expired on Wednesday, November 25th. Kiromic BioPharma had issued 1,250,000 shares in its IPO on October 16th. The total size of the offering was $15,000,000 based on an initial share price of $12.00. During Kiromic BioPharma's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kiromic BioPharma's stock price today?

One share of KRBP stock can currently be purchased for approximately $8.75.

How big of a company is Kiromic BioPharma?

Kiromic BioPharma has a market capitalization of $64.16 million. Kiromic BioPharma employs 13 workers across the globe.

What is Kiromic BioPharma's official website?

The official website for Kiromic BioPharma is www.kiromic.com.

How can I contact Kiromic BioPharma?

The company can be reached via phone at 832-968-4888 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.